Schwartz Investment Counsel Inc. Has $6.69 Million Position in Haemonetics Corporation $HAE

Schwartz Investment Counsel Inc. cut its stake in Haemonetics Corporation (NYSE:HAE) by 63.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 137,250 shares of the medical instruments supplier’s stock after selling 235,250 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Haemonetics were worth $6,690,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after purchasing an additional 971 shares during the period. Caxton Associates LLP bought a new position in Haemonetics in the 1st quarter valued at about $216,000. United Services Automobile Association bought a new position in Haemonetics in the 1st quarter valued at about $212,000. Empowered Funds LLC raised its position in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Haemonetics by 6.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HAE shares. Raymond James Financial reissued an “outperform” rating and issued a $90.00 price objective on shares of Haemonetics in a research note on Friday, November 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Needham & Company LLC lowered Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Barrington Research lifted their target price on Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. Finally, Citigroup dropped their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.40.

Haemonetics Trading Down 2.5%

HAE opened at $72.17 on Monday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The company has a fifty day moving average of $79.57 and a 200-day moving average of $65.91. The stock has a market cap of $3.38 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 1.36 and a beta of 0.29. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, sell-side analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.